A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus.
Animals
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
Cross Reactions
/ immunology
Disease Models, Animal
Genetic Vectors
/ genetics
Host-Pathogen Interactions
/ immunology
Immunization
Immunogenicity, Vaccine
Lentivirus
/ genetics
Mice
Vaccines, DNA
/ administration & dosage
Viral Envelope Proteins
/ immunology
Viral Vaccines
/ administration & dosage
Zika Virus
/ immunology
Zika Virus Infection
/ prevention & control
Zika vaccine
non-integrating lentiviral vector
Journal
Molecular therapy : the journal of the American Society of Gene Therapy
ISSN: 1525-0024
Titre abrégé: Mol Ther
Pays: United States
ID NLM: 100890581
Informations de publication
Date de publication:
05 08 2020
05 08 2020
Historique:
received:
13
02
2020
revised:
30
04
2020
accepted:
14
05
2020
pubmed:
3
6
2020
medline:
13
7
2021
entrez:
3
6
2020
Statut:
ppublish
Résumé
Zika virus, a member of the Flaviviridae family, is primarily transmitted by infected Aedes species mosquitoes. In 2016, Zika infection emerged as a global health emergency for its explosive spread and the remarkable neurological defects in the developing fetus. Development of a safe and effective Zika vaccine remains a high priority owing to the risk of re-emergence and limited understanding of Zika virus epidemiology. We engineered a non-integrating lentiviralvector(NILV)-based Zika vaccine encoding the consensus pre-membrane and envelope glycoprotein of circulating Zika virus strains. We further evaluated the immunogenicity and protective efficacy of this vaccine in both immunocompromised and immunocompetent mouse models. A single immunization in both mouse models elicited a robust neutralizing antibody titer and afforded full protection against Zika challenge as early as 7 days post-immunization. This NILV-based vaccine also induced a long-lasting immunity when immunized mice were challenged 6 months after immunization. Altogether, our NILV Zika vaccine provides a rapid yet durable protection through a single dose of immunization without extra adjuvant formulation. Our data suggest a promising Zika vaccine candidate for an emergency situation, and demonstrate the capacity of lentiviral vector as an efficient vaccine delivery platform.
Identifiants
pubmed: 32485138
pii: S1525-0016(20)30250-1
doi: 10.1016/j.ymthe.2020.05.016
pmc: PMC7403329
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Vaccines, DNA
0
Viral Envelope Proteins
0
Viral Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1772-1782Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Références
N Engl J Med. 2016 Mar 10;374(10):951-8
pubmed: 26862926
Lancet Infect Dis. 2016 Oct;16(10):1107
pubmed: 27676342
Cell Host Microbe. 2016 May 11;19(5):720-30
pubmed: 27066744
Nucleic Acids Res. 2007 Jan;35(Database issue):D21-5
pubmed: 17202161
Vaccine. 2015 Oct 13;33(42):5546-5552
pubmed: 26382601
Expert Rev Vaccines. 2005 Oct;4(5):615-27
pubmed: 16221064
PLoS One. 2014 Jul 24;9(7):e101644
pubmed: 25058148
Sci Immunol. 2017 Jul 21;2(13):
pubmed: 28733470
EBioMedicine. 2018 Oct;36:92-102
pubmed: 30201444
Nature. 2017 Mar 9;543(7644):248-251
pubmed: 28151488
J Clin Invest. 2003 Jun;111(11):1673-81
pubmed: 12782670
Science. 2016 Aug 19;353(6301):823-6
pubmed: 27417494
PLoS Negl Trop Dis. 2016 May 05;10(5):e0004658
pubmed: 27149521
Biochemistry. 1964 Jul;3:996-1008
pubmed: 14214095
Nucleic Acids Res. 1988 Nov 25;16(22):10881-90
pubmed: 2849754
Cell. 2000 Apr 14;101(2):173-85
pubmed: 10786833
Nature. 2016 Aug 4;536(7614):48-53
pubmed: 27338953
Curr Gene Ther. 2007 Oct;7(5):306-15
pubmed: 17979677
Proc Natl Acad Sci U S A. 2018 Dec 4;115(49):12477-12482
pubmed: 30455317
Cell Rep. 2019 Sep 3;28(10):2634-2646.e4
pubmed: 31484074
J Infect Dis. 2017 Dec 16;216(suppl_10):S897-S905
pubmed: 29267923
Lancet Infect Dis. 2010 May;10(5):338-49
pubmed: 20417416
Cell. 2017 Mar 9;168(6):1114-1125.e10
pubmed: 28222903
Cell Host Microbe. 2019 Nov 13;26(5):591-600.e4
pubmed: 31668877
N Engl J Med. 2016 Apr 21;374(16):1552-63
pubmed: 27028561
Emerg Infect Dis. 2017 Apr;23(4):611-615
pubmed: 27997333
Science. 2010 May 7;328(5979):745-8
pubmed: 20448183
Nature. 2016 Aug 25;536(7617):474-8
pubmed: 27355570
Emerg Infect Dis. 2008 Aug;14(8):1232-9
pubmed: 18680646
PLoS Pathog. 2019 Apr 18;15(4):e1007640
pubmed: 30998804
Virol J. 2013 Oct 22;10:311
pubmed: 24148652
J Immunol. 2001 Nov 1;167(9):5273-7
pubmed: 11673542
Adv Virus Res. 1986;31:103-68
pubmed: 2428213
Cell Rep. 2017 Feb 14;18(7):1751-1760
pubmed: 28199846
PLoS Negl Trop Dis. 2015 Oct 05;9(10):e0004081
pubmed: 26437302
J Virol. 2001 May;75(9):4040-7
pubmed: 11287553
J Immunol. 2010 May 1;184(9):4889-97
pubmed: 20357252
J Gene Med. 2006 Mar;8(3):265-74
pubmed: 16308885
Cell Host Microbe. 2010 Sep 16;8(3):271-83
pubmed: 20833378
JAMA. 1999 Jul 28;282(4):331-40
pubmed: 10432030
N Engl J Med. 2016 May 19;374(20):1981-7
pubmed: 27074377
Front Cell Infect Microbiol. 2018 Feb 15;8:44
pubmed: 29497604
Sci Rep. 2018 Jul 23;8(1):11043
pubmed: 30038228
N Engl J Med. 2002 Nov 21;347(21):1652-61
pubmed: 12444179
Clin Microbiol Infect. 2017 May;23(5):296-305
pubmed: 28062314
PLoS One. 2018 Aug 24;13(8):e0202820
pubmed: 30142207
Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17684-9
pubmed: 17095605
Science. 2016 Oct 14;354(6309):237-240
pubmed: 27708058
Sci Transl Med. 2017 Dec 13;9(420):
pubmed: 29237759
N Engl J Med. 2016 Sep 8;375(10):1002-4
pubmed: 27463941
PLoS One. 2012;7(11):e48644
pubmed: 23133649
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20382-7
pubmed: 19918062
Vaccines (Basel). 2019 Jun 24;7(2):
pubmed: 31238493